Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (July 2025)
40 slides from Prescient Therapeutics's investor presentation, Jul 4, 2025
Slide 1: SPP Presentation
SPP Presentation Join the CEO of PTX James McDonnell for a live and interactive shareholder briefing on Friday, 4th July 11am (AEST) where he will discuss the Share Purchase Plan, use of funds and how to participate. Register here: https://prescienttherapeutics.investorportal.com.au/shareholder-brie
Slide 2: About Prescient Therapeutics Limited (Prescient)
About Prescient Therapeutics Limited (Prescient) Prescient Therapeutics (ASX: PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies. Targeted Therapy PTX-100: is a first in class compound with the ability to block a
Slide 3: For personal use only
health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware t
Slide 4: Overview Presentation and Share Purchase Plan
For personal use only Overview Presentation and Share Purchase Plan July 2025 ASX: PTX ptxtherapeutics.com
Slide 5: Disclaimer and Safe Harbour
Disclaimer and Safe Harbour For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts
Slide 6: Targeted RAS therapies for cancers of unmet need
For personal use only Targeted RAS therapies for cancersRAS Targeted of unmet need therapies Platforms supporting for cancers of unmet need CAR-T therapies ✔ PTX-100 ✔ Potential application to 22% of all cancers ✔ OmniCAR ✔ PTX-100 (Advanced/Phase 2a) ✔ CellPryme
Slide 7: Our Lead Asset – PTX-100
For personal use only Our Lead Asset– PTX-100 ● Addressing high-mortality cancers of unmet need: T-Cell Lymphoma (TCL) ● Early results beyond benchmarks and existing drugs FDA support Targeted RAS therapies ● for cancers of unmet need ● US$1.8bn focus market* for TCL ● In Phase 2a for CTCL ✔ Potenti
Slide 8: Our technology: PTX-100 RAS Pathway disruptor
For personal use only Our technology: PTX-100 RAS Pathway disruptor ptxtherapeutics.com
Slide 9: What causes cancerous mutations?
What causes cancerous mutations? For personal use only Normal cell growth Normal cell Cell division Healthy tissue Abnormal cell growth Normal cell Genetic changes Cancerous cell division Malignant tumour Source: https://www.cancerfoundation.org.au/what-is-cancer-.html
Slide 10: Our Technology: PTX-100 First in Class Targeted Therapy
Our Technology For personal use only PTX-100 First in Class Targeted Therapy Inhibition of GGT-1 disrupts small GTPases including: the RAS family pathway • Mutations in RAS are present in approximately 22% of all human cancers1 • PTX-100 targets and blocks an enzyme called GGTase-1, disrupting the R
Slide 11: 22% of cancers have RAS mutations present
22% of cancers have RAS mutations present For personal use only Clinical Trial Basic Preclinical On Phase I Clinical PhaseTrial II Phase III MA Research Studies Market TCL Pancreas RAS Pathway Disruptor Lung PTX-100 Ovarian Colon Biliary Tract Others MA = Marketing Authorization Reference for mutati
Slide 12: Potential for accelerated approval for PTX-100 (CTCL)
Potential for accelerated approval for PTX-100 (CTCL) For personal use only Clinical Trial Basic Preclinical On Phase I Phase II MA Research Studies Market CTCL Pancreas RAS Pathway Disruptor Lung PTX-100 Ovarian Colon Biliary Tract Others MA = Marketing Authorization
Slide 13: First PTX-100 indication: Cutaneous T-cell Lymphoma (CTCL)
For personal use only First PTX-100 indication: Cutaneous T-cell Lymphoma (CTCL) ptxtherapeutics.com
Slide 14: Cutaneous T-cell Lymphoma (CTCL) Overview
Cutaneous T-cell Lymphoma (CTCL) Overview For personal use only ● A rare type of cancer of white blood cells (T cells), normally involved in immune function ● These cancerous T cells travel to and live in the skin, where they grow and divide uncontrollably, attacking the skin ● Limited options for p
Slide 15: Cutaneous T-cell Lymphomas (CTCL) a serious unmet need
Cutaneous T-cell Lymphomas For personal use only (CTCL) a serious unmet need “Unfortunately, T-Cell lymphomas (…) is universally incurable in patients that have not responded to initial therapy. So, we are in desperate need of a treatment that will allow patients to respond and give them prolonged r
Slide 16: PTX-100 Clinical Results
For personal use only PTX-100 Clinical Results ptxtherapeutics.com
Slide 17: For personal use only
“We are seeing responses in For personal use only our patients who weren’t responding to any other BEFORE AFTER treatments” — Professor Miles Prince Principal Investigator
Slide 18: PTX-100 Phase 1b responses
PTX-100 Phase 1b responses For personal use only Strong response rates in evaluable patients PTX-100 Benchmark1 Lymphir2,3 (Phase 1B)5 Response Rate 30% 36% 45% Clinical Benefit Rate 45% NA 64% 9-13 months CTCL Duration of Response 6.5 months (CTCL) 10.7 months 3-4 Months PTCL Serious Adverse Events
Slide 19: PTX-100: Favorable safety profile compared to peers
PTX-100: Favorable safety profile compared to peers For personal use only Recommended CTCL drugs, as outlined in international cancer treatment guidelines, have challenging safety profiles, with adverse events occurring in up to 70% of patients. PTX-100 HAS A FAVOURABLE SAFETY PROFILE ● Minimal ‘ser
Slide 20: PTX-100 into Phase 2
For personal use only PTX-100 into Phase 2 ptxtherapeutics.com
Slide 21: The building blocks of taking PTX-100 through Phase 2
The building blocks of taking PTX-100 through Phase 2 For personal use only Study design Patient recruitment FDA engagement • CTCL vs PTCL • Geographies • Ongoing dialogue • 2a / 2b design • Clinics • Goal: registration study • Existing data • Experts • FDA inputs on Phase 2b design • Dosages • Pati
Slide 22: Rationale of prioritising r/r CTCL over PTCL for Phase 2 trial
Rationale of prioritising r/r CTCL over PTCL for Phase 2 trial For personal use only CTCL (Cutaneous T Cell Lymphoma) PTCL (Peripheral T Cell Lymphoma) • Higher confidence – more data & responders More incidence than CTCL, but… • Greater need for new therapies • More existing and emerging competitio
Slide 23: Progressing PTX-100 Through Phase 2
Progressing PTX-100 Through Phase 2 For personal use only 500mg/m2 x 20 pts Dose r/r CTCL Randomization confirmation 2nd Line Phase 2a Dose Phase 2b Enrolment Optimisation Optimisation Efficacy X40 patients Committee X 75 pts (pts) 1000mg/m2 x 20 pts Up to 2 years Multicenter clinical trial • Phase
Slide 24: Regular Drug Development Process
Regular Drug Development Process For personal use only Clinical Trial Basic Preclinical On Phase I Clinical PhaseTrial II Phase III MA Regular drug Research Studies Market development Safety Dose finding Confirmatory process Studies and efficacy efficacy and studies safety studies MA = Marketing Aut
Slide 25: PTX-100 (CTCL) – Status Quo
PTX-100 (CTCL) – Status Quo For personal use only Clinical Trial Basic Preclinical On Phase I Clinical PhaseTrial II Phase III MA Research Studies Market PTX-100 (CTCL) Safety Dose finding Confirmatory Studies and efficacy efficacy and studies safety studies 2023 2024 Orphan Investigational Engageme
Slide 26: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only Years & Clinical Trial $$$ saved Basic Basic Preclinical Preclinical On On PhaseI I Clinical Phase Phase Phase Trial IIII MA III Phase MA Research Research Studies Studies Market Market PTX-100 (CTCL) Safety Dose finding Studies and e
Slide 27: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only Years & $$$2,3saved PTX-100 Benchmark Clinical 1 Trial Lymphir (Phase 1B) Basic Preclinical Preclinical On On PhaseI I Clinical Phase Phase Phase Trial IIII MA III Phase MA Response Rate Research Studies Studies 30% 36% 45% Market Mar
Slide 28: The path forward
For personal use only The path forward ptxtherapeutics.com
Slide 29: FDA Engagement and Enabling Outcomes
FDA Engagement and Enabling Outcomes For personal use only 2023 2024 2025 Orphan Drug Designation Investigational New Drug Fast Track Designation (ODD) (IND) Acceptance (FTD) 7 years guaranteed Groundwork for Phase 2 Increased FDA access and market exclusivity trials and FDA access rolling submissio
Slide 30: Advantages of orphan drugs
Advantages of orphan drugs For personal use only 7 7 years of Higher Sales are Total orphan Higher guaranteed prices more sales to chance of market resilient to reach phase 2 exclusivity cycles $US300B by progression1 in US 2028, in an (10 years in overall Europe) market of $1.5T 1. Based on Empiric
Slide 31: T-cell lymphomas (TCL): High unmet need = large market opportunity
T-cell lymphomas (TCL): For personal use only High unmet need = large market opportunity Total Addressable Market (TAM) 53% in the US • 27,263 new TCL cases per year UK GERMANY FRANCE based in the 8 major markets: US, France, USA (53%) SPAIN CHINA JAPAN ITALY Germany, Italy, Spain, UK and China • Po
Slide 32: Key milestones in the near future
Key milestones in the near future For personal use only Implementation will drive value Key Milestones Expected Timing (CY) First patient in and dosed with PTX-100 (FPID) Q2 (Complete) FDA Fast Track designation Q2 (Complete) EU Orphan Drug Designation Q3 First US site activated and recruiting Q3 Fi
Slide 33: Experienced team
Experienced team For personal use only Experienced team of drug developers and deal makers with track record in blood cancers Management Team Experienced gained in global companies Dr Rebecca Tunstall COO Board of Directors Melanie Farris Non-Executive Director
Slide 34: First PTX-100 indication: Cutaneous T-cell Lymphoma (CTCL)
First PTX-100 indication: Cutaneous T-cell Lymphoma (CTCL) For personal use only PTX-100 (Phase 1B) Response Rate 45% Clinical Benefit Rate 64% ● Results beyond benchmarks and existing drugs Duration of Response 10.7 months ● FDA support Serious Adverse Events4 4% ● US$1.8bn focus market* for TCL ●
Slide 35: Our Technology: PTX-100 First in Class Targeted Therapy
Our Technology PTX-100 First in Class Targeted Therapy For personal use only ● Potential application to 22% of cancers ● First in class enzyme inhibitor ● PTX-100 (TCL) = proof of concept ● Opportunity for significantly larger cancer markets
Slide 36: Share Purchase Plan
For personal use only Share Purchase Plan ptxtherapeutics.com
Slide 37: Summary of the SPP
Summary of the SPP For personal use only SPP Offer Raise Amount Targeting $7 million Proceeds from the SPP will support the advancement of the Company’s first-in-class targeted cancer therapy PTX-100, specifically by funding continued Phase 2 clinical development. Use of Funds Prescient is working t
Slide 38: Thank you
For personal use only Thank you ASX: PTX ptxtherapeutics.com
Slide 39: Appendix
For personal use only Appendix ptxtherapeutics.com
Slide 40: RAS pathway and its relevance to the development and treatment of cancers
RAS pathway – and its relevance to the development and treatment of cancers mutations? For personal use only RAS proteins are a family of small GTPase proteins crucial for cell signaling, regulating processes like cell growth, differentiation, and apoptosis. They act as molecular switches, cycling b
Prescient Therapeutics — Investor Presentation (July 2025) on 6ix